Portal de Periódicos da CAPES

Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION

2022; Springer Science+Business Media; Volume: 23; Issue: 1 Linguagem: Inglês

10.1186/s13063-022-06609-x

1745-6215

Jan Kloka, Benjamin Friedrichson, Stephanie Dauth, Ann Christina Foldenauer, Anita Bulczak-Schadendorf, Maria J. G. T. Vehreschild, Francisco Maio Matos, Antoni Riera‐Mestre, Thea van Asselt, Edoardo De Robertis, Vilma Traškaitė – Juškevičienė, Patrick Meybohm, Dana Tomescu, Karine Lacombe, Coen D.A. Stehouwer, Kai Zacharowski, Oliver Old, Markus Ketomaeki, Lea Grebe, Patrick Booms, Simone Lindau, Sebastian Zinn, Isabel Maushagen, Timo Wolf, Christoph Stephan, Cathy Weynants, Sylvia Daamen, P. Wülfroth, Thomas Steiner, Marinus van Hulst, Peter Kranke, Sebastian Hottenrott, Tobias Schlesinger, Benedikt Schmid, Daniel Röder, Eva Kranke, T. Haas, Philipp Schlesinger, Magdalena Sitter, Davide Valeri, Raquel Torres Iglesias, José María Mora‐Luján, Adriana Iriarte, Pau Cerdà, Neringa Vagulienė, Andrius Macas, Jolanta Litviniene, Kristina Balne, Catarina Monteiro, Inês Antunes Ferreira, Patrícia Couceiro, Pedro San Martin Soares, Sofia Beirão, Yasmine Abi Aad, Thibault Chiarabini, Mihai Popescu, Carla Kallen,

Thermal Regulation in Medicine

More than 2.7 million hospitalizations of COVID-19-infected patients have occurred in Europe alone since the outbreak of the coronavirus in 2020. Interventions against SARS-CoV-2 are still in high need to prevent admissions to ICUs worldwide. FX06, a naturally occurring peptide in humans and other mammals, has the potential to reduce capillary leak by improving endothelial dysfunction and thus preventing the deterioration of patients. With IXION, we want to investigate the potential of FX06 to prevent disease progression in hospitalized, non-intubated COVID-19 patients.